[1]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
　LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
点击复制

血脂水平与心房颤动相关性研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年6期
页码:
539
栏目:
综述
出版日期:
2021-06-25

文章信息/Info

Title:
Serum Lipid Level and Atrial Fibrillation
作者:
刘力黎 陈诚 张丽敏
 (陆军军医大学第二附属医院,重庆 400037)
Author(s):
LIU Lili; CHEN Cheng; ZHANG Limin
(The Second Affiliated Hospital of Army Medical University,Chongqing 400037 ,China)
关键词:
总胆固醇; 甘油三酯; 低密度脂蛋白胆固醇; 高密度脂蛋白胆固醇; 心房颤动
Keywords:
Total cholesterol; Triglycerides; Low-density lipoprotein cholesterol;  High-density lipoprotein cholesterol; Atrial fibrillation
DOI:
10.16806/j.cnki.issn.1004-3934.2021.06.015
摘要:
血脂水平增高及血脂变异性增加是动脉粥样硬化性心血管疾病的独立危险因素已成为临床共识，降胆固醇理论深入人心，然而近年来一些研究表明胆固醇水平的持续降低可能会增加心房颤动的发生风险，这一“胆固醇悖论”提示胆固醇的持续降低对于心血管疾病的发生可能是双刃剑。现针对甘油三酯、总胆固醇、低密度脂蛋白胆固醇及高密度脂蛋白胆固醇与心房颤动相关性的研究进展做一综述。
Abstract:
It has become a clinical consensus that the increase of blood lipid level and the increase of blood lipid variability are independent risk factors of atherosclerotic cardiovascular disease. The theory of lowering cholesterol has been widely accepted. However,in recent years,some studies have shown that the continuous decrease of cholesterol level may increase the risk of atrial fibrillation. This "cholesterol paradox" suggests that the continuous reduction of cholesterol may be a double-edged sword for the occurrence of cardiovascular disease. This article reviews the research progress of the relationship between triglycerides,total cholesterol,low-density lipoprotein cholesterol and high-density lipoprotein cholesterol and atrial fibrillation

参考文献/References:

[1] 上官娇玲,凌智瑜.心血管疾病风险指标新进展[J].心血管病学进展,2019,40(2):199-203.

[2] Annoura M,Ogawa M,Kumagai K,et al. Cholesterol paradox in patients with paroxysmal atrial fibrillation[J]. Cardiology,1999,92(1):21-27.

[3] Mourtzinis G,Kahan T,Bengtsson Bostrom K,et al. Relation between lipid profile and new-onset atrial fibrillation in patients with systemic hypertension (from the Swedish Primary Care Cardiovascular Database[SPCCD])[J]. Am J Cardiol,2018,122(1):102-107.

[4] Mora S,Akinkuolie AO,Sandhu RK,et al. Paradoxical association of lipoprotein measures with incident atrial fibrillation[J]. Circ Arrhythm Electrophysiol,2014,7(4):612-619.

[5] Li X,Gao L,Wang Z,et al. Lipid profile and incidence of atrial fibrillation:A prospective cohort study in China[J]. Clin Cardiol,2018,41(3):314-320.

[6] Watanabe H,Tanabe N,Watanabe T,et al. Metabolic syndrome and risk of development of atrial fibrillation:the Niigata preventive medicine study[J]. Circulation,2008,117(10):1255-1260.

[7] Alonso A,Yin X,Roetker NS,et al. Blood lipids and the incidence of atrial fibrillation:the multi-ethnic study of atherosclerosis and the framingham heart study[J]. J Am Heart Assoc,2014,3(5):e001211.

[8] Lee HJ,Lee SR,Choi EK,et al. Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation[J]. J Am Heart Assoc,2019,8(23):e012771.

[9] Trieb M,Kornej J,Knuplez E,et al. Atrial fibrillation is associated with alterations in HDL function,metabolism,and particle number[J]. Basic Res Cardiol,2019,114(4):27.

[10] Lopez FL,Agarwal SK,Maclehose RF,et al. Blood lipid levels,lipid-lowering medications,and the incidence of atrial fibrillation:the atherosclerosis risk in communities study[J]. Circ Arrhythm Electrophysiol,2012,5(1):155-162.

[11] Magnussen C,Niiranen TJ,Ojeda FM,et al. Sex differences and similarities in atrial fibrillation epidemiology,risk factors,and mortality in community cohorts[J]. Circulation,2017,136(17):1588-1597.

[12] Shang Y,Chen N,Wang Q,et al. Blood lipid levels and recurrence of atrial fibrillation after radiofrequency catheter ablation:a prospective study[J]. J Interv Card Electrophysiol,2020,57(2):221-231.

[13] Roh E,Chung HS,Lee JS,et al. Total cholesterol variability and risk of atrial fibrillation:A nationwide population-based cohort study[J]. PLoS One,2019,14(4):e0215687.

[14] Suzuki S. "Cholesterol paradox" in atrial fibrillation[J]. Circ J,2011,75(12):2749-2750.

[15] Watanabe H,Tanabe N,Yagihara N,et al. Association between lipid profile and risk of atrial fibrillation[J]. Circ J,2011,75(12):2767-2774.

[16] Psaty BM,Anderson M,Kronmal RA,et al. The association between lipid levels and the risks of incident myocardial infarction,stroke,and total mortality:the Cardiovascular Health Study[J]. J Am Geriatr Soc,2004,52(10):1639-1647.

[17] Suleiman M,Koestler C,Lerman A,et al. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation:a double-blind,placebo-controlled,randomized trial[J]. Heart Rhythm,2012,9(2):172-178.

[18] Canpolat U,Aytemir K,Yorgun H,et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation[J]. Europace,2015,17(12):1807-1815.

[19] Jiang H,Wang W,Wang C,et al. Association of pre-ablation level of potential blood markers with atrial fibrillation recurrence after catheter ablation:a meta-analysis[J]. Europace,2017,19(3):392-400.

[20] Folsom AR,Pankow JS,Tracy RP,et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease[J]. Am J Cardiol,2001,88(2):112-117.

[21] Barkas F,Elisaf M,Korantzopoulos P,et al. The CHADS2 and CHA 2DS2-VASc scores predict atrial fibrillation in dyslipidemic individuals:Role of incorporating low high-density lipoprotein cholesterol levels[J]. Int J Cardiol,2017,241:194-199.

[22] Boudi FB,Kalayeh N,Movahed MR. High-density lipoprotein cholesterol (HDL-C) levels independently correlates with cardiac arrhythmias and atrial fibrillation[J]. J Intensive Care Med,2020,35(5):438-444.

[23] Phillips MC. Molecular mechanisms of cellular cholesterol efflux[J]. J Biol Chem,2014,289(35):24020-24029.

[24] Li ZZ,Du X,Guo XY,et al. Association between blood lipid profiles and atrial fibrillation:a case-control study[J]. Med Sci Monit,2018,24:3903-3908.

相似文献/References:

[1]占小锋 张长磊 李刚.β肾上腺素受体阻滞剂对甘油三酯代谢的影响及其作用机制的阐述[J].心血管病学进展,2019,(9):1298.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.029]
　ZHAN Xiaofeng,ZHANG Changlei,LI Gang.Effect of -adrenergic Receptor Blockers on Triglyceride Metabolism and Mechanism[J].Advances in Cardiovascular Diseases,2019,(6):1298.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.029]
[2]彭彦人 郑华.甘油三酯与冠心病[J].心血管病学进展,2020,(10):1012.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.004]
　PENG YanrenZHENG Hua.Triglycerides and Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2020,(6):1012.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.004]

更新日期/Last Update: 2021-07-23